Ea Pharma Co., Ltd.

Ayatoshi Ando

Misato Noguchi

Yuki Saitou

Takashi Yamamoto

Masayuki Sugiki

Munetaka Tokumasu

Wataru Miyanaga

Itsuya Tanabe

Shunsuke Kageyama

Toshihiko Sugiura

Agung Eviryanti

Tomoko Miyazawa

Seiji Shiraishi

Hirokazu Ueno

Nobuhiko Hayakawa

Ryohei Yokoyama

Atsushi Tsuruta

Masatsugu Noguchi

Hiroyuki Eda

Mizuki Kawahira

Aya Kirihara

Tarou Nakamura

Kana Iwasaki

Manami Shuto

Mizuki Dohi

Ryuta Takashita

Ippei Kawanishi

Yui Yamaura

Harumi Tanaka

An object of the present invention is to provide a therapeutic agent for fatty liver diseases. The above object can be achieved by a therapeutic agent for a fatty liver disease, comprising a compound represented by the following formula (1): or a pharmaceutically acceptable salt thereof.

Therapeutic agent for fatty liver disease

Provided is a compound having &#x3b1;4 integrin inhibitory action. The compound is a sulfonamide derivative represented by the following formula (I), or pharmaceutically acceptable salt thereof: where Rto R, e to h, D, and B represent those as described in the specification.

Substituted benzenesulfonamides as inhibitors of alpha-4 beta-7 integrin activity

Sulfonamide compounds of a specific chemical structure in which a sulfonamide group having, as a substituent, a phenyl group or a heterocyclic group having a hetero atom(s) as a constituent element(s) is present at its terminal, and pharmaceutically acceptable salts thereof. These compounds are novel compounds having excellent &#x3b1;4 integrin-inhibitory action. The compounds have formulae represented by: 

Sulfonamide derivative and medicinal use thereof

Growing community of inventors

Chuo-ku, Japan

Ayatoshi Ando